

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 20, 2015
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 20, 2015.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Joni Bollinger, MD
James Lindsey, MD
Divya Ahuja, MD

Tan Platt, MD
Edward Behling, MD
Kashyap Patel, MD

Thomas Phillips, R.Ph.
Cheryl Hartvigsen, R.Ph.
Philip Mubarak, MD

SC DHHS Staff:

Bryan Amick, PharmD, MBA
Jim Bradford, MD
Damian Bridges, MHA
Constance Holloway, JD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, April 1, 2015

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Mylan, Inc	John Howard, PharmD	Epinephrine (Inj)
Janssen	†Phillip Wiegand, PharmD	SGLT2 Inhibitors
Abbvie	†Andrea Hume, MD	Androgenic Agents & Pancreatic Enzymes
AstraZeneca	Keith Latham, PharmD	SGLT2 Inhibitors
Boehringer Ingelheim	Erica Jessie	SGLT2 Inhibitors & DPP4 Inhibitors
Eli Lilly and Co	Jennifer Ward, RN, BSN	GLP-1 Agents & Platelet Aggregator Inhibitors
Prescription Alliance, LLC	†Ron Dunbar	Antibiotics, Inhaled
Novartis	†Sharon Hernandez, PharmD	Antibiotics, Inhaled

† Speaker gave time back to the Committee

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Classes for Re-Review

- Androgenic Agents
- Antibiotics, Inhaled
- Attention Deficit, Hyperactivity Disorder (Methylphenidate Agents)
- DPP4 Inhibitors and Combinations
- GLP1 Inhibitors
- SGLT2 Inhibitors and Combinations
- Pancreatic Enzymes
- Platelet Inhibitors

Classes for Review

- Epinephrine (Injectables)
- Glucocorticoids Inhaled (Nebulizer Solutions)

The chart below represents the recommendations from the P & T Committee:

ANDROGENIC AGENTS	
Preferred	Non-Preferred
AndroGel®	Androderm® Axiron® Fortesta® Testim® Testosterone Vogelxo®

ANTIBIOTICS, INHALED	
Preferred	Non-Preferred
Bethkis® Kitabis™	Cayston® TOBI® TOBI Pod haler® Tobramycin generic

ATTENTION DEFICIT, HYPERACTIVITY DISORDER (METHYLPHENIDATE AGENTS)	
Preferred	Non-Preferred
Daytrana® Dexmethylphenidate IR Focalin XR® Metadate CD® Metadate ER® Methylphenidate Methylphenidate ER Methylphenidate SR Quillivant XR™ Ritalin LA®	Concerta® Dexmethylphenidate XR Focalin® Methylin® Chewable Methylin® Solution Methylphenidate CD Methylphenidate LA Ritalin® Ritalin SR®

DPP4 INHIBITORS AND COMBINATIONS	
Preferred	Non-Preferred
Janumet® Januvia® Jentaduetto® Tadjenta®	Kazano Kombiglyze XR® Nesina Onglyza® Oseni

GLP1 INHIBITORS	
Preferred	Non-Preferred
Bydureon® Byetta® Tanzeum®	Trulicity® Victoza®

SGLT2 INHIBITORS AND COMBINATIONS	
Preferred	Non-Preferred
Invokana® Farxiga® Invokamet® Xigduo™ XR	Jardiance®

PANCREATIC ENZYMES	
Preferred	Non-Preferred
Creon® Pancrelipase Zenpep®	Pancreaze® Pertzye® Viokace® Ultresa®

PLATELET INHIBITORS	
Preferred	Non-Preferred
Aggrenox® Brilinta® Clopidogrel	Dipyridamole Effient® Persantine Plavix® Ticlopidine Zontivity®

EPINEPHRINE (INJECTABLES)	
Preferred	Non-Preferred
EPIPEN® / EPIPEN JR®	Adrenaclick® Auvi-Q® Epinephrine Injection

GLUCOCORTICOIDS INHALED (NEBULIZER SOLUTIONS)	
Preferred	Non-Preferred
Pulmicort Respules®	Budesonide Inhalation

5. **Old Business**

None

6. **New Business**

Bryan spoke to the relevance of the P&T Committee. Currently, there are approximately 1 million SC Medicaid recipients. 700,000 are enrolled in MCOs and the remaining 300,000 are Fee-for-Service (FFS). Of those 300,000 recipients, approximately 100,000 are in limited benefit plans (e.g., Healthy Connections, HIV/AIDS, TB, etc.), 100,000 are Duals and the remaining 100,000 are enrolled in the full service benefit (FFS).

SC DHHS will implement the next phase of the VBID (Valued Based Design) plan on July 1, 2015. This phase will remove the \$3.40 copay from Behavioral Health (except controlled substances) and Diabetic medications.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Classes for Re-Review

Androgenic Agents
Antibiotics, Inhaled
Attention Deficit, Hyperactivity Disorder (Methylphenidate Agents)
DPP4 Inhibitors and Combinations
GLP1 Inhibitors
SGLT2 Inhibitors and Combinations
Pancreatic Enzymes
Platelet Inhibitors

Classes for Review

Epinephrine (Injectables)
Glucocorticoids Inhaled (Nebulizer Solutions)

8. **Closing Comments**

The next meeting will be held on Wednesday, August 5, 2015, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:54 p.m.